GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (FRA:1HM) » Definitions » Price-to-Owner-Earnings

Adaptive Biotechnologies (FRA:1HM) Price-to-Owner-Earnings : (As of Jun. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Price-to-Owner-Earnings?

As of today (2024-06-25), Adaptive Biotechnologies's share price is €3.028. Adaptive Biotechnologies does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Adaptive Biotechnologies's Price-to-Owner-Earnings or its related term are showing as below:


FRA:1HM's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.075
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-25), Adaptive Biotechnologies's share price is €3.028. Adaptive Biotechnologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-1.38. Therefore, Adaptive Biotechnologies's PE Ratio (TTM) for today is At Loss.

As of today (2024-06-25), Adaptive Biotechnologies's share price is €3.028. Adaptive Biotechnologies's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.38. Therefore, Adaptive Biotechnologies's PE Ratio without NRI for today is At Loss.


Adaptive Biotechnologies Price-to-Owner-Earnings Historical Data

The historical data trend for Adaptive Biotechnologies's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Price-to-Owner-Earnings Chart

Adaptive Biotechnologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Adaptive Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Adaptive Biotechnologies's Price-to-Owner-Earnings

For the Biotechnology subindustry, Adaptive Biotechnologies's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adaptive Biotechnologies's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Price-to-Owner-Earnings falls into.



Adaptive Biotechnologies Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Adaptive Biotechnologies's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.028/-1.54
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adaptive Biotechnologies  (FRA:1HM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Adaptive Biotechnologies Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Adaptive Biotechnologies (FRA:1HM) Business Description

Traded in Other Exchanges
Address
1165 Eastlake Avenue East, Seattle, WA, USA, 98109
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease ("MRD") in patients with multiple myeloma ("MM"), B cell acute lymphoblastic leukemia ("ALL") and chronic lymphocytic leukemia ("CLL") and is also available as a CLIA-validated laboratory developed test ("LDT") for patients with other lymphoid cancers, including diffuse large B-cell lymphoma ("DLBCL").

Adaptive Biotechnologies (FRA:1HM) Headlines

No Headlines